Dong O, Manga N, Zhong Y, Zhang Y, Krause T, Griffin J, Herring WL, Wolowacz S. Use of patient-reported outcomes as key drivers in cost-effectiveness models: a review of UK National Institute for Health and Care Excellence health technology assessments. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S78. doi: 10.1016/j.jval.2023.03.405
Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res. 2022 Dec 1;11(18):1349-63. doi: 10.2217/cer-2021-0194
Herring WL, Gould IG, Wittrup-Jensen V, Kuti E, Mettam S, Ertle J, Wolowacz S. A conceptual model for the economic evaluation of emerging nonalcoholic steatohepatitis therapies: the impact of treatment efficacy profiles on health outcomes. Poster presented at the 2020 SMDM 18th Biennial European Conference (Conference cancelled); June 16, 2020.
Herring W, Pearson I, Purser M, Nakhaipour HR, Haiderali A, Wolowacz S, Jayasundara K. Cost effectiveness of ofatumumab plus chlorambucil in first-line chronic lymphocytic leukaemia in Canada. Pharmacoeconomics. 2016 Jan;34(1):77-90. doi: 10.1007/s40273-01509332-5
Herring WL, Pearson IV, Purser MF, Nakhaipour HR, Haiderali A, Wolowacz SE, Jayasundara K. Cost-effectiveness of ofatumumab plus chlorambucil in first line chronic lymphocytic leukemia in Canada. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):PA633.